2026 SITC EU Immuno-Oncology
Drug Development Summit

Sept. 2026 in Lausanne, Switzerland - Venue and dates to be determined

I'm Interested

Thank you to our partners. 

Collaborative Partner

Marketing Partner

Marketing Partner

The 2026 EU Immuno-Oncology Drug Development Summit will educate and engage the European IO community on the next wave of IO therapeutics and ensure that active, innovative, new therapies are rapidly and appropriately moved into clinical testing.

Sign up below to get an update when registration opens.

Organizers

Madiha Derouazi, PhD
Swiss Biotech Association 

Ivan Diaz-Padilla, MD, PhD
Ipsen

Pedro Romero, MD

Pedro Romero, MD
Novigenix

Michael Stumpp, PhD
Molecular Partners AG

Zhen Su, MD, MBA
Marengo Therapeutics

Program Description

The 2026 EU Immuno-Oncology Drug Development Summit will educate and engage the European IO community on the next wave of IO therapeutics and ensure that active, innovative, new therapies are rapidly and appropriately moved into clinical testing.

The program will be a key forum for continuing exploration and discussion of best practices for modern IO drug development, including study design, regulatory pathways and emerging technologies.

Target Audience

The target audience for this program is investors and physicians and scientists in academia, industry (including emerging biotech companies), and regulatory agencies in the US and Europe who have an interest in the strategic, preclinical, clinical and regulatory aspects of efficient IO drug development.

Learning Objectives

Understand Optimal Clinical Trial Design

Understand optimal clinical trial design specific to immuno-oncology therapeutics (including trial designs, dose-finding, and endpoints) that reflect regulatory expectations and requirements.

Integrate Objectives

Integrate scientific and regulatory objectives to develop preclinical and clinical strategies that drive efficient development of immuno-oncology therapeutics.

Foster International Relationships

Foster international relationships between regulatory agencies, industry/biotech members, and academic investigators in Europe and the US to develop effective strategies for the development of immuno-oncology therapeutics through discussion of case studies, lessons learned and looking ahead across mechanisms (including deeper dives into immune cell engagers, cell therapies and AI for IO drug development).

Describe Key Resources

Describe key informational resources and implement best practices regarding the development of immuno-oncology therapeutics across treatments beyond PD-I (Multi-/Bi-specific Antibodies), novel modalities (Antibody-drug Conjugates (ADCs)), and next-wave combination therapies (Radioimmunotherapy, Immunogenic Cell Death targets, Oncolytic Virus, etc).